Exelon Patch rivastigmine regulatory update

FDA approved an sNDA from Novartis to expand the label of Exelon Patch rivastigmine transdermal patch to include treatment of severe Alzheimer's disease with the 13.3 mg/24 hour dose. The acetylcholi...